Global Pharmacogenomics Market (2020 to 2030) - by Service, Technology, Application, End-user, and Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
The global pharmacogenomics market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
This report is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
- 23andMe, Inc.
- Abbott Laboratories
- Admera Health, LLC
- Agena Biosciences, Inc.
- Astra Zeneca PLC
- Bayer AG
- Becton, Dickinson and Company
- Cancer Genetics, Inc.
- Dynamic DNA Laboratories
- Empire Genomics LLC
- F. Hoffmann-La Roche Ltd
- geneOmbio Technologies Pvt Ltd.
- Genomic Health, Inc.
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics Inc.
- Oneome LLC
- Opko Health, Inc.
- Pathway Genomics Corporation
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Teva Pharmaceuticals Industries Ltd.
- Thermo Fisher Scientific Inc.
- Transgenomic, Inc.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Five Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region.
Key Topics Covered:
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter's Five Forces Analysis
3 Segmentation of Global Market by Service
3.1 Market Overview by Service
3.3 SNP Identification
3.5 Other Services
4 Segmentation of Global Market by Technology
4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.6 Mass Spectrometry
4.7 Other Technologies
5 Segmentation of Global Market by Application
5.1 Market Overview by Application
5.3 Infectious Diseases
5.6 Pain Management
5.7 Other Applications
6 Segmentation of Global Market by End User
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes
7 Segmentation of Global Market by Region
7.1 Geographic Market Overview 2019-2030
7.2 North America Market 2019-2030 by Country
7.2.1 Overview of North America Market
7.3 European Market 2019-2030 by Country
7.3.1 Overview of European Market
7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2019-2030 by Country
7.4.1 Overview of Asia-Pacific Market
7.4.6 South Korea
7.4.7 Rest of APAC Region
7.5 South America Market 2019-2030 by Country
7.5.4 Rest of South America Market
7.6 MEA Market 2019-2030 by Country
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Other National Markets
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
9 Investing in Global Market: Risk Assessment and Management
9.1 Risk Evaluation of Global Market
9.2 Critical Success Factors (CSFs)
For more information about this report visit https://www.researchandmarkets.com/r/xw9els
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900